Table 3.

miRNAs derived from sEVs as a biomarker for cancer diagnosis.

miRNA species	Expression condition	Source	Cancer	Reference
miR-27a & miR130a	Increase	plasma	CRC	[22]
miR-7641	Upregulated	SW620-cell lysates	CRC	[23]
miR-17–5p	Upregulated	serum	NSCLC	[392]
miR-451a	High upregulation in NSCLC patients with recurrence	Plasma	NSCLC	[393]
let-7d-3p & miR-30d-5p	Decreased expression level in CINI II + group when compared with the CINI I+ group	plasma	Cervical cancer	[394]
miR-1246	Downregulated	Serum	Aggressive prostate cancer	[395]
miR-21.miR-222 & miR-124–3p	Higher in high grade gliomas	Serum	Glioma	[396]
miR-210	Increase	Serum	Glioma	[397]
miR-223–3p	Higher in invasive ductal carcinoma in situ (DCIS) breast cancer	Plasma	DCIS breast cancer	[398]
268miR-23b	Lower expression in patients than healthy people	Plasma	Gastric cancer	[399]
miR-6807–5p & miR-6856–5P	Higher expression	Urinary	Gastric cancer	[400]
miR-191, miR-21, & miR-451a	Elevated expression	Serum	Pancreatic neoplasm	[401]
266miR-122 & miR-21	Decreased	Serum	Hepatocellular carcinoma	[402]
miR-204–5p	Elevated	Urinary of transgenic mice overexpressing human PRCC-TFE3 fusion gene	Xp 11.2 Translocation renal cell carcinoma	[403]
miR-145 & miR-200c	Higher expression	Serum	Ovarian Cancer	[404]